Floatz logo

Trastuzumab Emtansine

PR-Negative Breast Cancer

Jules Bordet Instituteantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the PR-Negative Breast Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Northwestern University
Phase 3BBB
Epirubicin
Massachusetts General Hospital
Phase 2BB
Pembrolizumab
Massachusetts General Hospital
Phase 2BB
Cyclophosphamide
Massachusetts General Hospital
Phase 3BB
Capecitabine
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Trastuzumab Emtansine is also rated in:

Breast Inflammatory CarcinomaDormant
BB
Indicative ·
67 / 100
View asset →
breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →